Evidence-based recommendations on topical treatment and phototherapy of psoriasis: Systematic review and expert opinion of a panel of dermatologists

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue SUPPL. 3, 2012, Pages 1-10

  Paul, C ^a   Gallini, A ^b   Archier, E ^c   Castela, E ^d   Devaux, S ^a   Aractingi, S ^e   Aubin, F ^f   Bachelez, H ^g   Cribier, B ^h   Joly, P ⁱ   Jullien, D ^j   Le Maitre M ^k   Misery, L ^l   Richard, M A ^c   Ortonne, J P ^d  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b Faculté de Médecine Centre Hospitalo universitaire   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁱ UNIVERSITÉ DE ROUEN   (France)

^j EDOUARD HERRIOT HOSPITAL   (France)

^k NONE

^l BREST UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; CORTICOSTEROID; DITHRANOL; PLACEBO; PSORALEN; SALICYLIC ACID; STEROID; TAR; TAZAROTENE; VITAMIN D;

BASAL CELL CARCINOMA; CANCER RISK; CATARACT; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DERMATOLOGIST; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; EYE INJURY; HUMAN; LENTIGO; MAINTENANCE THERAPY; MONOTHERAPY; PATIENT COMPLIANCE; PHOTOAGING; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; PUVA; REVIEW; RISK FACTOR; SKIN CANCER; SKIN MANIFESTATION; SKINFOLD; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TOPICAL TREATMENT; TREATMENT FAILURE; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; DERMATOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; PHOTOTHERAPY; PSORIASIS;

EID: 84860122150     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04518.x     Document Type: Review

References (59)

1. Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010; 24: 1075-1082.
2. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70.
3. Mason AR, Mason J, Cork M, et al. Topical Treatments for Chronic Plaque Psoriasis. The Cochrane Library, Issue 2, 2009.
4. bbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004; 151: 283-297. (Pubitemid 39215142)
5. Schmutz JL, Jeanmougin M, Martin S, et al. Recommandations de la société française de photodermatologie pour la PUVAthérapie systémique dans le psoriasis vulgaire. Ann Dermatol Venereol 2000; 127: 73-79.
6. Beani JC, Jeanmougin M,. Photothérapie UVB à spectre étroit dans le psoriasis vulgaire: utilisation pratique et préconisations de la société française de photodermatologie. Ann Dermatol Venereol 2010; 137: 21-31.
7. Lapolla W, Yentzer BA, Bagel J, et al. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol 2011; 64: 936-949.
8. Haddican MM, Bhutani T, McClelland PB, Koo JY,. Why are there significant differences in published narrowband ultraviolet B dosimetry recommendations? The need for national standardization of phototherapy treatment. J Am Acad Dermatol 2011; 65: 411-414.
9. Archier E, Devaux S, Castela E, et al. Efficacy of Psoralen UV-A therapy vs Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 11-21.
10. Archier E, Devaux S, Castela E, et al. Carcinogenic risks of Psoralen UV-A Therapy and Narrowband UV-B Therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 22-31.
11. Archier E, Devaux S, Castela E, et al. Ocular damage in patients with psoriasis treated by Psoralen UV-A therapy or Narrow Band UVB therapy. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 32-35.
12. Castela E., Archier E., Devaux S, et al. Topical corticosteroids in plaque-psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 36-46.
13. Castela E., Archier E, Devaux S, et al. Topical corticosteroids in plaque-psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 47-51.
14. Devaux S, Castela A., Archier E, et al. Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 52-60.
15. Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 61-67.
16. Paul C, Gourraud PA, Bronsard V, et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2010; 24: 2-9.
17. Paul C, Gallini A, Maza A, et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011; 25: 2-11.
18. van Tulder M, Furlan A, Bombardier C, et al. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine (Phila Pa 1976) 2003; 28: 1290-1299. (Pubitemid 36734620)
19. Sackett DL, Richardson WS, Rosenberg WM, et al. Evidence-based medicine: how to practice and teach EBM. Churchill Livingstone, London (UK), 1997.
20. Roddy E, Zhang W, Doherty M, et al. Evidence-based clinical guidelines: a new system to better determine true strength of recommendation. J Eval Clin Pract 2006; 12: 347-352. (Pubitemid 43806715)
21. Yones SS, Palmer RA, Garibaldinos TT, et al. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006; 142: 836-842. (Pubitemid 44079782)
22. Markham T, Rogers S, Collins P, et al. Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003; 139: 325-328. (Pubitemid 36330579)
23. Gordon PM, Diffey BL, Matthews JN, Farr PM,. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999; 41: 728-732. (Pubitemid 29514028)
24. Stern RS, Nichols KT, Väkevä LH,. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336: 1041-1045. (Pubitemid 27163855)
25. Bruynzeel I, Bergman W, Hartevelt HM, et al. 'High single-dose' European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124: 49-55.
26. Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108-112. (Pubitemid 29333701)
27. Hannuksela-Svahn A, Pukkala E, Läärä E, Poikolainen K, Karvonen J,. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000; 114: 587-590. (Pubitemid 30415349)
28. Stern RS, PUVA Follow up Study,. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-761. (Pubitemid 32391161)
29. Stern RS,. Ocular lens findings in patients treated with PUVA. Photochemotherapy Follow-Up-Study. J Invest Dermatol 1994; 103: 534-538. (Pubitemid 24314841)
30. Malanos D, Stern RS,. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol 2007; 57: 231-237. (Pubitemid 47048879)
31. Alvarez F, Meyer N, Gourraud PA, Paul C,. CONSORT adoption and quality of reporting of randomized controlled trials: a systematic analysis in two dermatology journals. Br J Dermatol 2009; 161: 1159-1165.
32. Senter TP, Stimson DH, Charles G, Brand RJ,. Comparison of two therapeutic regimens using the same topical corticoid for stable psoriasis. J Med 1983; 139: 657-662. (Pubitemid 14207243)
33. Pacifico A, Daidone R, Peris K,. A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 153-157. (Pubitemid 43740514)
34. Katz HI, Gross E, Buxman M, et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol 1991; 25: 1175-1178.
35. Poulin Y, Papp K, Bissonnette R, et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. Cutis 2010; 85: 43-50.
36. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160. (Pubitemid 43727399)
37. Fleming C, Ganslandt C, Leese GP,. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. J Drugs Dermatol 2010; 9: 969-974.
38. Traulsen J, Hughes-Formella BJ,. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology 2003; 207: 166-172. (Pubitemid 37034346)
39. Guzzo C, Lazarus G, Goffe BS, et al. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. J Am Acad Dermatol 1996; 34: 429-433. (Pubitemid 26083819)
40. Rizova E, Corroller M,. Topical calcitriol - studies on local tolerance and systemic safety. Br J Dermatol 2001; 144 (Suppl. 58): 3-10.
41. Sips AJ, Netelenbos JC, Barto R, et al. Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasis. J Am Acad Dermatol 1994; 30 (6): 966-969. (Pubitemid 24166564)
42. Blum R, Schwartzel E, Siskin S, Epinette WW,. Evaluating the safety of calcipotriene 30 g per day in patients with psoriasis: a parallel group, vehicle-controlled study. J Clin Pharmacol 1998; 38: 368-372. (Pubitemid 28194178)
43. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26: 736-743.
44. Camarasa JM, Ortonne JP, Dubertret L,. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatol Treat 2003; 14: 8-13. (Pubitemid 36417421)
45. Ruzicka T, Lorenz B,. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol 1998; 138: 254-258. (Pubitemid 28114127)
46. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-323.
47. Tiplica GS, Salavastru CM,. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 905-912.
48. Fouéré S, Adjadj L, Pawin H,. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005; 19: 2-6. (Pubitemid 41726918)
49. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-736. (Pubitemid 44352553)
50. van de Kerkhof PC, de Hoop D, de Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292-298. (Pubitemid 30451575)
51. Zaghloul SS, Goodfield MJ,. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408-414. (Pubitemid 38469243)
52. Ersser SJ, Cowdell FC, Latter SM, Healy E,. Self-management experiences in adults with mild-moderate psoriasis: an exploratory study and implications for improved support. Br J Dermatol 2010; 163: 1044-1049.
53. Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008; 59: 1009-1016.
54. Richards HL, Fortune DG, Griffiths CE,. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 370-379.
55. Uhlenhake EE, Kurkowski D, Feldman SR,. Conversations on psoriasis-what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatol Treat 2010; 21: 6-12.
56. Finlay AY, Edwards PH, Harding KG,. "Fingertip unit" in dermatology. Lancet 1989; 2: 155.
57. Poulin Y, Papp KA, Wasel NR, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010; 49: 1368-1375.
58. Balica S, Bernier C, Mazereeuw-Hautier J, et al. Ann Dermatol Venereol 2011; 138: 337-353.
59. Pouplard C Gourraud PA, Meyer N,. Are we giving patients enough information on how to use topical treatments? Analysis of 767 prescriptions in psoriasis. Br J Dermatol 2011; 165: 1332-1336.